Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gilead Sciences, Inc. (NASDAQ:GILD) said the Food and Drug Administration (FDA) has put a clinical hold on its studies evaluating its investigation anti-CD47 immunotherapy magrolimab for acute myeloid leukemia (AML), a month after the biopharmaceuticla company discontinued a Phase 3 study of the drug for higher-risk myelodysplastic syndromes. The firm said it has paused the screening and enrollment of patients in its trials, but patients already enrolled in the AML clinical studies can continue to receive treatment and be monitored per the existing study protocol.

Gilead Sciences told by FDA to pause patient enrollment in leukemia drug trials

Gilead Sciences said on Monday the U.S. Food and Drug Administration had placed a partial clinical hold on initiating new patients in the U.S. studies for drug to treat a type of blood cancer.

US FDA puts Gilead Sciences blood cancer drug studies on hold

Gilead Sciences Inc. GILD, -0.81% said Monday that the U.S. Food and Drug Administration has put a partial clinical hold on U.S. studies evaluating a treatment for acute myeloid leukemia. Screening and enrollment of new participants in the study of magrolimab will be paused effective immediately, Gilead said in a release, while patients already enrolled in acute myeloid leukemia clinical studies can continue receiving treatment.

Gilead says FDA hits pause on study of leukemia treatment

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the initiation of new patients in U.S. studies evaluating magrolimab to treat acute myeloid leukemia (AML). The FDA action follows the previously announced discontinuation of the Phase 3 ENHANCE study of magrolimab in higher-risk myelodysplastic syndromes (HR-MDS). Effective immediately, screening and enrollment of new.

Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML

FOSTER CITY, Calif. & NASHVILLE, Tenn.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Meharry Medical College, one of the nation's oldest and largest historically Black academic health science centers, today announced the publication of a new supplemental issue of Meharry Medical College's Journal of Health Care for the Poor and Underserved. It details the impact of the Gilead COMPASS Initiative® – the company's 10-year, more than $100 million collaborative initiative that seeks to.

Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States

Pfizer

Investing in the biotech sector is like embarking on an expedition across a vast ocean of potential. Making the right decisions can yield bountiful rewards, while wrong turns can lead to substantial setbacks.

Undervalued Biotech Gems: 2 Stocks Combining Dividends With Healthy Returns

Gilead (GILD) enters into a deal with Tentarix Biotherapeutics to discover and develop novel therapies for cancer and inflammation.

Gilead (GILD), Tentarix To Develop Cancer, Inflammation Therapies

Gilead Sciences said on Tuesday it had entered into an agreement with privately held Tentarix Biotherapeutics to develop therapies for cancer and inflammatory diseases.

Gilead ties up with Tentarix for cancer, inflammatory disease therapies

FOSTER CITY, Calif. & SAN DIEGO--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) and Tentarix Biotherapeutics today announced that the companies established three multi-year collaborations leveraging Tentarix's proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases. Designed to enhance both therapeutic benefit and safety, these molecules have the potential to conditionally target immune cells related.

Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation

Amgen

CRISPR Therapeutics

Many healthcare stocks suffer from COVID fatigue as profits fall amid a global decline in the virus' spread. But medical innovations and technological breakthroughs are rapidly transforming the healthcare landscape, and biotech stocks are garnering unprecedented attention in the investment community.

The 3 Best Biotech Stocks to Buy in August

Despite their falling stock prices, both of these companies have solid prospects. Pfizer has been busy making deals -- something that is already paying off.

2 High-Yield Dividend Stocks to Buy on the Dip

Gilead Sciences has experienced a boom-bust-recovery cycle, with its fortunes changing after acquiring Pharmasset and obtaining a cure for HCV. Revenues have been stagnant for nearly a decade, with the company relying heavily on its HIV franchise today. The second quarter earnings report showed mixed results, with non-Veklury sales growing solidly but a slight pullback in earnings guidance was seen.

Gilead Sciences: Mixed Signals, Again

Gilead's (GILD) Q2 earnings miss on litigation charges while revenues beat on strong oncology and HIV franchise.

Gilead's (GILD) Q2 Earnings Miss, Revenues Beat on Oncology

With a daily gain of 4.63% and an Earnings Per Share (EPS) of 4.43, Gilead Sciences Inc ( GILD , Financial) has been attracting attention in the investment community. This article aims to answer the pressing question: is Gilead Sciences (GILD) fairly valued?

Is Gilead Sciences (GILD) Fairly Valued? An In-Depth Analysis

Gilead Sciences, Inc. (NASDAQ:GILD ) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Jacquie Ross - Vice President, Investor Relations Daniel O'Day - Chairman and Chief Executive Officer Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - Chief Financial Officer Cindy Perettie - Executive Vice President, Kite Conference Call Participants Geoff Meacham - Bank of America Chris Schott - JPMorgan Tyler Van Buren - TD Cowen Terrence Flynn - Morgan Stanley Bill Jahangiri - Truist Brian Abrahams - RBC Capital Markets Carter Gould - Barclays Matthew Dellatorre - Goldman Sachs Colin Bristow - UBS Evan Seigerman - BMO Capital Markets Joseph Catanzaro - Piper Sandler Mohit Bansal - Wells Fargo Simon Baker - Redburn Operator Hello, everyone. Thank you for attending Gilead Sciences' Second Quarter 2023 Earnings Conference Call.

Gilead Sciences, Inc. (GILD) Q2 2023 Earnings Call Transcript

The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Gilead (GILD) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Gilead Sciences (GILD) came out with quarterly earnings of $1.34 per share, missing the Zacks Consensus Estimate of $1.60 per share. This compares to earnings of $1.58 per share a year ago.

Gilead Sciences (GILD) Q2 Earnings Lag Estimates

Two of Gilead's cancer drugs topped second-quarter sales expectations Thursday. But GILD stock could be hamstrung on an earnings miss.

Will An Earnings Miss Cloud Gilead's Massive Cancer Treatment Growth?

Gilead Sciences Inc.'s stock GILD, -0.20% slid 2% in after-hours trade Thursday, after the drug company posted weaker-than-expected second-quarter profit and lowered its guidance. Foster City, Calif.

Gilead's stock slides 2% after Q2 profit lags consensus and as company lowers guidance

Gilead Sciences on Thursday reported lower second-quarter profit as costs from a legal settlement and sharply lower sales of its COVID-19 treatment offset another strong performance by HIV drugs.

Gilead quarterly profit falls on COVID sales drop, legal settlement charge

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter of 2023. “It was another strong quarter for Gilead, with continued commercial and clinical momentum,” said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. “11% year-over-year growth across our base business was driven by our diverse portfolio of therapies for HIV, Oncology, and Liver Disease. We received positive regulatory updates for six of o.

Gilead Sciences Announces Second Quarter 2023 Financial Results

Biogen

Regeneron Pharmaceuticals

The biotechnology sector is huge and growing. Grand View Research forecasts that the industry will reach $3.88 trillion by 2030, growing at a compound annual growth rate of 14%.

Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its second-quarter 2023 results.

Gilead (GILD) Gears Up to Report Q2 Earnings: What's in Store?

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) approved Trodelvy® (sacituzumab govitecan) as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting. The approval by the European Commission follows the positive opinion of.

European Commission Approves Gilead's Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today presented new data reinforcing the efficacy, safety, and tolerability profile of lenacapavir, including patient-reported outcomes (PRO) from the Phase 2/3 CAPELLA trial. These latest findings underscore the role of lenacapavir, the first long-acting injectable HIV treatment medication administered twice-yearly, as a person-centric therapy option and its transformative potential impact on the future of coordinated H.

News for Gilead Sciences Stock (GILD)